Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a study of suramin given as a 4 h infusion of 350 mg/m2 per day for 5 days, followed by 350 mg/m2 weekly from day 14, plus mitomycin C (MMC) 12 mg/m2 given every 5 weeks starting on day 14. No responses were seen in the 15 patients treated with suramin and MMC. One patient experienced lethal toxic epidermonecrolysis. Other toxicities were mild and consisted of a maculopapular skin rash in 5 patients, temporary sensory peripheral neuropathy in 4 patients and proteinuria in 2 patients. Mild nausea and vomiting occurred in 3, mild leucopenia or thrombocytopenia in 2 and moderate infection in 3 patients. The median time to treatment failure was 28 days. The median survival time was 155 days. Suramin in combination with MMC has acceptable toxicity but showed no therapeutic activity in patients with NSCLC in this trial.
- Non Small Cell Lung Cancer
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
- Cancer Research